# Enzymatic therapy for celiac Engineered enzymes and enzyme-target inhibitors are moving toward pharmaceutical protection from gluten exposure in celiac disease — a Barcelona-designed gastric enzyme validated in mouse models, a transglutaminase-2 inhibitor showing histologic protection in human trials, and a $35M Takeda-funded oral enzyme program whose later trial stage reportedly worsened mucosal damage. Source: https://en.bioecon.ru/technology/enzymatic-therapy-celiac/ Updated: 2026-08-18 ## Overview and value chain Markers: [EC: EU/US drug-development regulatory pathway for celiac disease therapeutics | OECD: Bio-pharmaceuticals | Regulator: EMA (EU), FDA (USA)] Enzymatic therapy for celiac disease applies engineered enzymes and enzyme-targeting inhibitors to protect celiac patients from the autoimmune intestinal damage triggered by dietary gluten, as a pharmaceutical complement to the lifelong gluten-free diet that remains the only established treatment. Researchers at the University of Barcelona and the Institut de Biologia Molecular de Barcelona (IBMB-CSIC) designed "celiacase," a recombinant enzyme active at gastric pH that works synergistically with pepsin to degrade gluten immunogenic peptides — including the highly reactive 33-mer fragment from wheat alpha-gliadin — before they reach the duodenum, reducing intestinal atrophy, inflammation, antibody response and dysbiosis at low doses in mouse models; the molecule is patented and a spin-off is being formed to advance it toward clinical use. In Germany, Dr. Falk Pharma has funded university research on ZED1227, an oral inhibitor of transglutaminase 2 (TG2) — the enzyme that deamidates gluten peptides and triggers the celiac immune cascade — which in a 2024 study protected patients consuming 3 grams of daily gluten for six weeks from measurable intestinal mucosal damage and inflammation at a 100 mg daily dose. On the commercial supplement side, DSM-Firmenich markets Tolerase G, an Aspergillus niger-derived prolyl endoprotease (AN-PEP) sold as a dietary-supplement ingredient to support digestion of incidental gluten exposure, though it lacks the same clinical-trial evidence base as the prescription-track candidates. In the US, Seattle's PvP Biologics developed KumaMax, an oral enzyme designed to break down immune-reactive gluten in the stomach, under a 2016 deal in which Takeda committed $35 million in R&D funding plus an option to acquire PvP; the program advanced into Takeda's pipeline as zamaglutenase (TAK-062), and industry reporting indicates its later-stage trial showed increased mucosal damage rather than protection, after which the program was discontinued. The key directions of enzymatic therapy for celiac are: 1. **Gastric-active gluten-degrading enzymes (Gastric-Active Gluten-Degrading Enzymes):** engineered or recombinant proteases active at low stomach pH that degrade immunogenic gluten peptides before they reach the duodenum. 2. **Transglutaminase-2 (TG2) inhibition (Transglutaminase-2 (TG2) Inhibition):** small-molecule inhibitors blocking the enzyme that deamidates gluten peptides and triggers the autoimmune cascade, rather than degrading gluten itself. 3. **Oral supplement-grade digestive enzymes (Oral Supplement-Grade Digestive Enzymes):** commercially marketed enzyme blends intended to aid incidental gluten digestion, sold without the same clinical evidence bar as prescription-track therapeutics. 4. **Staged biotech-to-pharma enzyme partnerships (Staged Biotech-to-Pharma Enzyme Partnerships):** large pharmaceutical companies funding a smaller biotech's engineered-enzyme platform through milestone-based option-to-acquire deals. ### Sectoral value chain ``` [enzyme/inhibitor design] ──> [preclinical validation] ──> [clinical gluten-challenge trial] ──> [efficacy/safety evaluation] │ (regulatory decision or program halt) │ ▼ [patient use/sale] <─── [commercial/OTC formulation] <─────────────────┘ ``` ### Value chain levels | Level | Description | Key inputs/outputs | |:---|:---|:---| | **Enzyme/Inhibitor Design** | engineering a recombinant enzyme or small-molecule inhibitor targeting a specific step of gluten immunogenicity | **In:** target mechanism (gluten peptide or TG2), protein/molecule engineering.
**Out:** candidate enzyme/inhibitor. | | **Preclinical Validation** | testing the candidate in biochemical assays or animal models for gluten-degradation or TG2-inhibition activity | **In:** candidate enzyme/inhibitor.
**Out:** preclinical efficacy/safety data. | | **Clinical Gluten-Challenge Trial** | dosing celiac patients with the study candidate alongside controlled gluten exposure | **In:** preclinical data, patient cohort, gluten challenge protocol.
**Out:** trial-stage clinical data. | | **Efficacy/Safety Evaluation** | comparing histologic, immunologic and symptom outcomes against a defined clinical bar | **In:** trial-stage clinical data.
**Out:** regulatory decision or program discontinuation. | | **Commercial/OTC Formulation (Parallel Track)** | packaging an enzyme as a dietary-supplement ingredient without the prescription-drug trial bar | **In:** enzyme ingredient.
**Out:** OTC supplement product. | | **Patient Use/Sale** | prescription or over-the-counter sale of the resulting therapeutic or supplement | **In:** approved therapeutic or OTC product.
**Out:** patient use, revenue. | Cross-cutting technologies of the sector: - **Recombinant gastric-active proteases (Recombinant Gastric-Active Proteases):** enzymes engineered for peak activity at gastric pH, synergizing with native pepsin to pre-digest immunogenic gluten fragments. - **Transglutaminase-2 inhibitor chemistry (Transglutaminase-2 Inhibitor Chemistry):** small molecules blocking the deamidation step that increases gluten peptides' affinity for HLA-DQ2/DQ8 antigen presentation. - **Prolyl endopeptidase supplementation (Prolyl Endopeptidase Supplementation):** Aspergillus niger-derived AN-PEP enzymes marketed as digestive aids for incidental gluten exposure. --- ## US The US contributed the original enzyme-engineering platform behind one of the most closely watched — and ultimately discontinued — programs in the field, developed by a small Seattle biotech before a major pharma partnership took over its clinical advancement. ### Seattle-originated enzyme engineering, staged pharma option-to-acquire, later-stage program discontinuation - **PvP Biologics (Seattle) / Takeda:** PvP Biologics developed KumaMax, an oral enzyme designed to break down immune-reactive gluten in the stomach; under a 2016 deal, Takeda committed $35 million in R&D funding with an option to acquire PvP on completion of defined milestones. The program advanced under Takeda as zamaglutenase (TAK-062) — reported to degrade 6 grams of gluten in Phase 1 — but industry reporting indicates a later trial stage showed increased mucosal damage (a falling villus-height-to-crypt-depth ratio) rather than protection, after which the program was discontinued. --- ## CN Public information on a dedicated Chinese enzymatic-therapy-for-celiac originator was not confirmed with company-specific detail in this pass; Chinese-language coverage of the field consists of medical-education and market-report content on celiac disease and gluten-free products rather than a confirmed domestic drug-development originator. ### no confirmed company-specific detail this pass, medical-education and gluten-free-market coverage only - **No confirmed company-specific detail this pass:** the sources returned for this region were general medical-education content (disease mechanism explainers, a gluten-free product market report) rather than a source confirming a specific Chinese enzymatic-therapy-for-celiac originator. --- ## EU The EU anchors both an academic gastric-enzyme discovery moving toward spin-off commercialization and a pharma-funded transglutaminase inhibitor already showing human clinical protection, alongside a long-established OTC digestive-enzyme ingredient business. ### gastric-active enzyme spin-off formation, TG2-inhibitor clinical protection, established OTC AN-PEP ingredient - **University of Barcelona / IBMB-CSIC:** designed "celiacase," a recombinant enzyme active at gastric pH that degrades gluten immunogenic peptides — including the 33-mer fragment from wheat alpha-gliadin — synergistically with pepsin before they reach the duodenum, reducing intestinal atrophy, inflammation, antibody response and dysbiosis in mouse models; the molecule is patented, with a spin-off being formed to advance clinical development. - **Dr. Falk Pharma:** funded university research (Tampere University, University of Oulu) on ZED1227, an oral TG2 inhibitor that in a 2024 study protected patients consuming 3 grams of daily gluten for six weeks from measurable intestinal mucosal damage and inflammation at a 100 mg daily dose, with the researchers cautioning it remains premature to call it a gluten-free-diet replacement. - **DSM-Firmenich:** markets Tolerase G, an Aspergillus niger-derived prolyl endoprotease (AN-PEP) sold as a dietary-supplement ingredient supporting digestion of incidental gluten exposure, without the same clinical evidence base as the prescription-track candidates. --- ## Leading companies and research institutes | Company / Institute | Country | Key products / platforms | Tech features | Status 2026 | |:---|:---|:---|:---|:---| | **University of Barcelona / IBMB-CSIC** | 🇪🇸 Spain | *Celiacase gastric enzyme* | mouse-model efficacy; patented; spin-off forming | Research | | **Dr. Falk Pharma** | 🇩🇪 Germany | *ZED1227 TG2 inhibitor* | blocked gluten-induced mucosal damage at 100mg/day in 2024 study | Commercial | | **DSM-Firmenich** | 🇨🇭 Switzerland | *Tolerase G (AN-PEP)* | OTC digestive-enzyme ingredient; no prescription-grade trial data | Commercial | | **Takeda** | 🇯🇵 Japan | *Zamaglutenase (TAK-062)* | ex-PvP Biologics KumaMax; degraded 6g gluten in Phase 1; later discontinued | Commercial | --- ## Tech stack and innovations The stack spans gastric-active enzyme engineering, enzyme-target inhibition and commercial OTC enzyme supplementation. 1. **Gastric-active recombinant proteases (Gastric-Active Recombinant Proteases):** - engineered proteins reach maximum activity at gastric pH (~2), working alongside native pepsin to degrade immunogenic gluten peptides before they reach the duodenum, then self-inactivating in the intestine. - case: the University of Barcelona/IBMB-CSIC's celiacase reduced intestinal atrophy, inflammation, antibody response and dysbiosis at low doses in mouse models. 2. **TG2-inhibitor small-molecule chemistry (TG2-Inhibitor Small-Molecule Chemistry):** - blocking transglutaminase 2 prevents the deamidation step that increases gluten peptides' binding affinity to HLA-DQ2/DQ8, upstream of the immune cascade rather than degrading gluten directly. - case: Dr. Falk Pharma-funded ZED1227 protected patients from measurable mucosal damage and inflammation during a 6-week, 3g/day gluten challenge at 100mg daily. 3. **Engineered oral gluten-degrading enzymes (Engineered Oral Gluten-Degrading Enzymes):** - a recombinant enzyme engineered to break down immune-reactive gluten fragments in the stomach before intestinal exposure. - case: PvP Biologics/Takeda's zamaglutenase (TAK-062) degraded 6 grams of gluten in a Phase 1 study, though a later trial stage reportedly showed worsened mucosal damage, illustrating the difficulty of ensuring degradation byproducts remain non-immunogenic at scale. --- ## Value chains and production pipelines ### Industrial pipeline of enzyme/inhibitor development for celiac disease (EMA/FDA drug-development framework) ``` ┌───────────────────────────┐ ┌───────────────────────────┐ │ 1. Enzyme/inhibitor design│ ───> │ 2. Preclinical validation │ └───────────────────────────┘ └───────────────────────────┘ │ ▼ ┌───────────────────────────┐ ┌───────────────────────────┐ │ 4. Efficacy/safety eval. │ <─── │ 3. Clinical gluten-challenge│ └───────────────────────────┘ └───────────────────────────┘ │ ▼ ┌───────────────────────────┐ ┌───────────────────────────┐ │ 5. Commercial/OTC formul. │ ───> │ 6. Patient use/sale │ └───────────────────────────┘ └───────────────────────────┘ ``` #### Stage 1: Enzyme/inhibitor design A recombinant enzyme or small-molecule inhibitor is engineered to target a specific step of gluten immunogenicity — direct peptide degradation or TG2 inhibition. #### Stage 2: Preclinical validation The candidate is tested in biochemical assays or animal models for gluten-degradation or TG2-inhibition activity, measuring markers such as intestinal atrophy, inflammation and antibody response. #### Stage 3: Clinical gluten-challenge trial Celiac patients on the candidate are exposed to a controlled daily gluten dose over a defined period, with a placebo arm for comparison. #### Stage 4: Efficacy/safety evaluation Histologic (villus-height-to-crypt-depth ratio), immunologic and symptom outcomes are compared against a defined clinical bar, leading either toward regulatory advancement or program discontinuation. #### Stage 5: Commercial/OTC formulation (parallel track) Independently of the prescription-drug pathway, an enzyme such as AN-PEP can be formulated and sold as a dietary-supplement ingredient without the same trial requirements. #### Stage 6: Patient use/sale The resulting prescription therapeutic (if approved) or OTC supplement reaches celiac patients as a complement to the gluten-free diet.